Corcept Therapeutics CORT -4.84% Get Free Report has outperformed the market over the past 20 years by 7.21% on an annualized ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31 ...

Corcept Therapeutics Trading Up 1.3 % Shares of CORT opened at $68.62 on Friday. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 54.46 and a beta of 0.15. The ...

If you're interested in broad exposure to the Small Cap Growth segment of the US equity market, look no further than the iShares S&P Small-Cap 600 Growth ETF (IJT), a passively managed exchange traded ...

As of 12:05:15 GMT-4. Market open.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US. The importance of biosimilars only continues ...